tickerreport.com
Positivewww.tickerreport.com ·
manning napier advisors llc decreases stock position in johnson johnson jnj
WB_1331_HEALTH_TECHNOLOGIESWB_1350_PHARMACEUTICALSWB_621_HEALTH_NUTRITION_AND_POPULATIONEPU_ECONOMY_HISTORIC
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article reports a routine institutional portfolio adjustment in Johnson & Johnson (JNJ) stock. No direct commercial mechanism affecting JNJ's product pricing, input costs, or supply chain is identified. The dividend increase and earnings beat are positive signals but do not create scarcity or margin squeeze. Impact is limited to equity sentiment for JNJ shareholders.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Manning & Napier Advisors reduced JNJ stake by 14.6% in Q4 2026, selling 21,457 shares.
- JNJ stock opened at $221.17, 12-month range $146.12-$251.71.
- JNJ Q1 earnings $2.70/share, beating estimates.
- JNJ announced quarterly dividend increase to $1.34, payable June 9, 2026.